Forte Biosciences, Inc. (FBRX)
76.94
+0.02
(+0.03%)
USD |
NASDAQ |
Aug 24, 16:00
76.94
0.00 (0.00%)
After-Hours: 20:00
Forte Biosciences Total Assets (Quarterly) : 205.74M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 205.74M |
| March 31, 2026 | 67.22M |
| December 31, 2025 | 82.78M |
| September 30, 2025 | 97.09M |
| June 30, 2025 | 107.78M |
| March 31, 2025 | 47.46M |
| December 31, 2024 | 61.56M |
| September 30, 2024 | 17.95M |
| June 30, 2024 | 26.08M |
| March 31, 2024 | 32.02M |
| December 31, 2023 | 38.98M |
| September 30, 2023 | 47.88M |
| June 30, 2023 | 31.18M |
| March 31, 2023 | 36.71M |
| December 31, 2022 | 42.00M |
| September 30, 2022 | 45.13M |
| June 30, 2022 | 39.72M |
| March 31, 2022 | 41.30M |
| December 31, 2021 | 43.31M |
| September 30, 2021 | 47.39M |
| June 30, 2021 | 52.89M |
| Date | Value |
|---|---|
| March 31, 2021 | 57.07M |
| December 31, 2020 | 61.24M |
| September 30, 2020 | 22.73M |
| June 30, 2020 | 28.31M |
| March 31, 2020 | 18.63M |
| December 31, 2019 | 7.658M |
| September 30, 2019 | 70.75M |
| June 30, 2019 | 85.23M |
| March 31, 2019 | 94.73M |
| December 31, 2018 | 103.08M |
| September 30, 2018 | 90.35M |
| June 30, 2018 | 87.34M |
| March 31, 2018 | 78.74M |
| December 31, 2017 | 92.07M |
| September 30, 2017 | 102.17M |
| June 30, 2017 | 110.77M |
| March 31, 2017 | 34.29M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | 56.36M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | 1.743B |
| Alnylam Pharmaceuticals, Inc. | 5.559B |
| Anika Therapeutics, Inc. | 183.47M |
| Savara, Inc. | 192.14M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 21.95M |
| Shareholders Equity (Quarterly) | 183.79M |
| Current Ratio | 10.01 |